nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilutamide—POR—Doxorubicin—ovarian cancer	0.435	0.767	CbGbCtD
Nilutamide—CYP2C8—Paclitaxel—ovarian cancer	0.0781	0.137	CbGbCtD
Nilutamide—CYP2C9—Paclitaxel—ovarian cancer	0.0544	0.0959	CbGbCtD
Nilutamide—AR—oviduct—ovarian cancer	0.00968	0.135	CbGeAlD
Nilutamide—Flutamide—CYP1B1—ovarian cancer	0.00679	0.792	CrCbGaD
Nilutamide—POR—myometrium—ovarian cancer	0.00524	0.073	CbGeAlD
Nilutamide—POR—uterine cervix—ovarian cancer	0.00408	0.0568	CbGeAlD
Nilutamide—POR—decidua—ovarian cancer	0.00389	0.0541	CbGeAlD
Nilutamide—POR—endometrium—ovarian cancer	0.00369	0.0514	CbGeAlD
Nilutamide—AR—myometrium—ovarian cancer	0.0031	0.0431	CbGeAlD
Nilutamide—AR—Regulation of Androgen receptor activity—SPDEF—ovarian cancer	0.00302	0.0641	CbGpPWpGaD
Nilutamide—POR—bone marrow—ovarian cancer	0.00288	0.0402	CbGeAlD
Nilutamide—POR—female gonad—ovarian cancer	0.00278	0.0387	CbGeAlD
Nilutamide—POR—vagina—ovarian cancer	0.00276	0.0385	CbGeAlD
Nilutamide—POR—testis—ovarian cancer	0.00247	0.0343	CbGeAlD
Nilutamide—AR—epithelium—ovarian cancer	0.00243	0.0338	CbGeAlD
Nilutamide—AR—uterine cervix—ovarian cancer	0.00241	0.0336	CbGeAlD
Nilutamide—POR—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.00233	0.0495	CbGpPWpGaD
Nilutamide—AR—decidua—ovarian cancer	0.0023	0.032	CbGeAlD
Nilutamide—AR—endometrium—ovarian cancer	0.00218	0.0303	CbGeAlD
Nilutamide—AR—gonad—ovarian cancer	0.00202	0.0281	CbGeAlD
Nilutamide—AR—uterus—ovarian cancer	0.00201	0.028	CbGeAlD
Nilutamide—AR—Nuclear Receptors—NR5A1—ovarian cancer	0.00181	0.0384	CbGpPWpGaD
Nilutamide—AR—female reproductive system—ovarian cancer	0.00181	0.0251	CbGeAlD
Nilutamide—POR—lymph node—ovarian cancer	0.00179	0.0249	CbGeAlD
Nilutamide—Enzalutamide—ABCB1—ovarian cancer	0.00178	0.208	CrCbGaD
Nilutamide—CYP2C8—endometrium—ovarian cancer	0.00176	0.0245	CbGeAlD
Nilutamide—AR—female gonad—ovarian cancer	0.00164	0.0229	CbGeAlD
Nilutamide—AR—vagina—ovarian cancer	0.00163	0.0227	CbGeAlD
Nilutamide—CYP2C19—vagina—ovarian cancer	0.00151	0.0211	CbGeAlD
Nilutamide—CYP2C8—female reproductive system—ovarian cancer	0.00146	0.0203	CbGeAlD
Nilutamide—AR—testis—ovarian cancer	0.00146	0.0203	CbGeAlD
Nilutamide—AR—Nuclear Receptor transcription pathway—NR5A1—ovarian cancer	0.00143	0.0304	CbGpPWpGaD
Nilutamide—CYP2C8—vagina—ovarian cancer	0.00132	0.0184	CbGeAlD
Nilutamide—CYP2C9—female reproductive system—ovarian cancer	0.0013	0.0181	CbGeAlD
Nilutamide—CYP2C8—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—ovarian cancer	0.00125	0.0265	CbGpPWpGaD
Nilutamide—CYP2C8—testis—ovarian cancer	0.00118	0.0164	CbGeAlD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—BCL9—ovarian cancer	0.00114	0.0242	CbGpPWpGaD
Nilutamide—CYP2C8—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—ovarian cancer	0.00113	0.0241	CbGpPWpGaD
Nilutamide—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—ovarian cancer	0.00111	0.0236	CbGpPWpGaD
Nilutamide—AR—lymph node—ovarian cancer	0.00106	0.0147	CbGeAlD
Nilutamide—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—ovarian cancer	0.00101	0.0216	CbGpPWpGaD
Nilutamide—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—ovarian cancer	0.00101	0.0215	CbGpPWpGaD
Nilutamide—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—ovarian cancer	0.000922	0.0196	CbGpPWpGaD
Nilutamide—AR—Nuclear Receptors—PGR—ovarian cancer	0.0009	0.0191	CbGpPWpGaD
Nilutamide—AR—Nuclear Receptor transcription pathway—PGR—ovarian cancer	0.000711	0.0151	CbGpPWpGaD
Nilutamide—AR—Notch-mediated HES/HEY network—PARP1—ovarian cancer	0.000706	0.015	CbGpPWpGaD
Nilutamide—Visual impairment—Paclitaxel—ovarian cancer	0.000646	0.00212	CcSEcCtD
Nilutamide—Weight decreased—Docetaxel—ovarian cancer	0.000642	0.00211	CcSEcCtD
Nilutamide—AR—FOXA1 transcription factor network—BRCA1—ovarian cancer	0.00064	0.0136	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—BARD1—ovarian cancer	0.000638	0.0136	CbGpPWpGaD
Nilutamide—Blood alkaline phosphatase increased—Epirubicin—ovarian cancer	0.000637	0.00209	CcSEcCtD
Nilutamide—Pneumonia—Docetaxel—ovarian cancer	0.000637	0.00209	CcSEcCtD
Nilutamide—Diarrhoea—Chlorambucil—ovarian cancer	0.000636	0.00209	CcSEcCtD
Nilutamide—Paraesthesia—Vinorelbine—ovarian cancer	0.000636	0.00209	CcSEcCtD
Nilutamide—Dyspnoea—Vinorelbine—ovarian cancer	0.000631	0.00207	CcSEcCtD
Nilutamide—Abnormal vision—Doxorubicin—ovarian cancer	0.000616	0.00202	CcSEcCtD
Nilutamide—Decreased appetite—Vinorelbine—ovarian cancer	0.000616	0.00202	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000611	0.00201	CcSEcCtD
Nilutamide—AR—FOXA1 transcription factor network—SOD1—ovarian cancer	0.000607	0.0129	CbGpPWpGaD
Nilutamide—Pain—Vinorelbine—ovarian cancer	0.000606	0.00199	CcSEcCtD
Nilutamide—Constipation—Vinorelbine—ovarian cancer	0.000606	0.00199	CcSEcCtD
Nilutamide—Asthenia—Topotecan—ovarian cancer	0.000594	0.00195	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.000593	0.0126	CbGpPWpGaD
Nilutamide—Alopecia—Paclitaxel—ovarian cancer	0.000592	0.00194	CcSEcCtD
Nilutamide—Hot flush—Epirubicin—ovarian cancer	0.000592	0.00194	CcSEcCtD
Nilutamide—Vomiting—Chlorambucil—ovarian cancer	0.000591	0.00194	CcSEcCtD
Nilutamide—Blood alkaline phosphatase increased—Doxorubicin—ovarian cancer	0.000589	0.00193	CcSEcCtD
Nilutamide—Menopausal symptoms—Epirubicin—ovarian cancer	0.000587	0.00193	CcSEcCtD
Nilutamide—Pruritus—Topotecan—ovarian cancer	0.000586	0.00192	CcSEcCtD
Nilutamide—Feeling abnormal—Vinorelbine—ovarian cancer	0.000584	0.00191	CcSEcCtD
Nilutamide—Asthenia—Melphalan—ovarian cancer	0.000582	0.00191	CcSEcCtD
Nilutamide—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000579	0.0019	CcSEcCtD
Nilutamide—CYP2C8—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000575	0.0122	CbGpPWpGaD
Nilutamide—Pruritus—Melphalan—ovarian cancer	0.000573	0.00188	CcSEcCtD
Nilutamide—Tension—Paclitaxel—ovarian cancer	0.000573	0.00188	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—ATF3—ovarian cancer	0.000571	0.0121	CbGpPWpGaD
Nilutamide—Rhinitis—Docetaxel—ovarian cancer	0.00057	0.00187	CcSEcCtD
Nilutamide—Cardiac failure—Epirubicin—ovarian cancer	0.000568	0.00186	CcSEcCtD
Nilutamide—Nervousness—Paclitaxel—ovarian cancer	0.000567	0.00186	CcSEcCtD
Nilutamide—Diarrhoea—Topotecan—ovarian cancer	0.000566	0.00186	CcSEcCtD
Nilutamide—Hypoaesthesia—Docetaxel—ovarian cancer	0.000565	0.00185	CcSEcCtD
Nilutamide—Back pain—Paclitaxel—ovarian cancer	0.000564	0.00185	CcSEcCtD
Nilutamide—Urinary tract disorder—Docetaxel—ovarian cancer	0.000561	0.00184	CcSEcCtD
Nilutamide—Abdominal pain—Vinorelbine—ovarian cancer	0.00056	0.00184	CcSEcCtD
Nilutamide—Body temperature increased—Vinorelbine—ovarian cancer	0.00056	0.00184	CcSEcCtD
Nilutamide—Oedema peripheral—Docetaxel—ovarian cancer	0.00056	0.00184	CcSEcCtD
Nilutamide—Urethral disorder—Docetaxel—ovarian cancer	0.000557	0.00183	CcSEcCtD
Nilutamide—Diarrhoea—Melphalan—ovarian cancer	0.000555	0.00182	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Epirubicin—ovarian cancer	0.000554	0.00182	CcSEcCtD
Nilutamide—Nausea—Chlorambucil—ovarian cancer	0.000552	0.00181	CcSEcCtD
Nilutamide—Hot flush—Doxorubicin—ovarian cancer	0.000548	0.0018	CcSEcCtD
Nilutamide—Visual impairment—Docetaxel—ovarian cancer	0.000548	0.0018	CcSEcCtD
Nilutamide—Dizziness—Topotecan—ovarian cancer	0.000547	0.0018	CcSEcCtD
Nilutamide—Menopausal symptoms—Doxorubicin—ovarian cancer	0.000543	0.00178	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—SMARCA4—ovarian cancer	0.000543	0.0115	CbGpPWpGaD
Nilutamide—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000541	0.00178	CcSEcCtD
Nilutamide—Anaemia—Paclitaxel—ovarian cancer	0.000539	0.00177	CcSEcCtD
Nilutamide—Vomiting—Topotecan—ovarian cancer	0.000526	0.00173	CcSEcCtD
Nilutamide—Malaise—Paclitaxel—ovarian cancer	0.000526	0.00173	CcSEcCtD
Nilutamide—Cardiac failure—Doxorubicin—ovarian cancer	0.000525	0.00172	CcSEcCtD
Nilutamide—Syncope—Paclitaxel—ovarian cancer	0.000523	0.00172	CcSEcCtD
Nilutamide—Leukopenia—Paclitaxel—ovarian cancer	0.000522	0.00171	CcSEcCtD
Nilutamide—Rash—Topotecan—ovarian cancer	0.000522	0.00171	CcSEcCtD
Nilutamide—Dermatitis—Topotecan—ovarian cancer	0.000521	0.00171	CcSEcCtD
Nilutamide—Blood creatinine increased—Epirubicin—ovarian cancer	0.000519	0.0017	CcSEcCtD
Nilutamide—Headache—Topotecan—ovarian cancer	0.000519	0.0017	CcSEcCtD
Nilutamide—Vomiting—Melphalan—ovarian cancer	0.000515	0.00169	CcSEcCtD
Nilutamide—CYP2C19—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000514	0.0109	CbGpPWpGaD
Nilutamide—Loss of consciousness—Paclitaxel—ovarian cancer	0.000513	0.00168	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Doxorubicin—ovarian cancer	0.000513	0.00168	CcSEcCtD
Nilutamide—Rash—Melphalan—ovarian cancer	0.000511	0.00168	CcSEcCtD
Nilutamide—Dermatitis—Melphalan—ovarian cancer	0.000511	0.00168	CcSEcCtD
Nilutamide—Cough—Paclitaxel—ovarian cancer	0.000509	0.00167	CcSEcCtD
Nilutamide—Asthenia—Vinorelbine—ovarian cancer	0.000508	0.00167	CcSEcCtD
Nilutamide—Dry skin—Epirubicin—ovarian cancer	0.000508	0.00167	CcSEcCtD
Nilutamide—Hypertension—Paclitaxel—ovarian cancer	0.000504	0.00165	CcSEcCtD
Nilutamide—Alopecia—Docetaxel—ovarian cancer	0.000502	0.00165	CcSEcCtD
Nilutamide—Pruritus—Vinorelbine—ovarian cancer	0.000501	0.00164	CcSEcCtD
Nilutamide—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000499	0.00164	CcSEcCtD
Nilutamide—Chest pain—Paclitaxel—ovarian cancer	0.000497	0.00163	CcSEcCtD
Nilutamide—AR—Coregulation of Androgen receptor activity—BRCA1—ovarian cancer	0.000493	0.0105	CbGpPWpGaD
Nilutamide—Nausea—Topotecan—ovarian cancer	0.000492	0.00161	CcSEcCtD
Nilutamide—Discomfort—Paclitaxel—ovarian cancer	0.000491	0.00161	CcSEcCtD
Nilutamide—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000489	0.0016	CcSEcCtD
Nilutamide—Dry mouth—Paclitaxel—ovarian cancer	0.000486	0.00159	CcSEcCtD
Nilutamide—Diarrhoea—Vinorelbine—ovarian cancer	0.000484	0.00159	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.000483	0.0103	CbGpPWpGaD
Nilutamide—Nausea—Melphalan—ovarian cancer	0.000481	0.00158	CcSEcCtD
Nilutamide—AR—Nuclear Receptors—ESR1—ovarian cancer	0.000481	0.0102	CbGpPWpGaD
Nilutamide—Blood creatinine increased—Doxorubicin—ovarian cancer	0.00048	0.00158	CcSEcCtD
Nilutamide—Influenza—Epirubicin—ovarian cancer	0.000479	0.00157	CcSEcCtD
Nilutamide—Back pain—Docetaxel—ovarian cancer	0.000478	0.00157	CcSEcCtD
Nilutamide—Oedema—Paclitaxel—ovarian cancer	0.000476	0.00156	CcSEcCtD
Nilutamide—Dry skin—Doxorubicin—ovarian cancer	0.00047	0.00154	CcSEcCtD
Nilutamide—Shock—Paclitaxel—ovarian cancer	0.000469	0.00154	CcSEcCtD
Nilutamide—CYP2C9—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000468	0.00996	CbGpPWpGaD
Nilutamide—Dizziness—Vinorelbine—ovarian cancer	0.000468	0.00154	CcSEcCtD
Nilutamide—Angina pectoris—Epirubicin—ovarian cancer	0.000466	0.00153	CcSEcCtD
Nilutamide—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000462	0.00151	CcSEcCtD
Nilutamide—Hyperhidrosis—Paclitaxel—ovarian cancer	0.00046	0.00151	CcSEcCtD
Nilutamide—Anaemia—Docetaxel—ovarian cancer	0.000457	0.0015	CcSEcCtD
Nilutamide—Anorexia—Paclitaxel—ovarian cancer	0.000454	0.00149	CcSEcCtD
Nilutamide—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000452	0.00148	CcSEcCtD
Nilutamide—Vomiting—Vinorelbine—ovarian cancer	0.00045	0.00148	CcSEcCtD
Nilutamide—Rash—Vinorelbine—ovarian cancer	0.000446	0.00146	CcSEcCtD
Nilutamide—Dermatitis—Vinorelbine—ovarian cancer	0.000446	0.00146	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000445	0.00146	CcSEcCtD
Nilutamide—Headache—Vinorelbine—ovarian cancer	0.000444	0.00146	CcSEcCtD
Nilutamide—Syncope—Docetaxel—ovarian cancer	0.000444	0.00146	CcSEcCtD
Nilutamide—Influenza—Doxorubicin—ovarian cancer	0.000443	0.00145	CcSEcCtD
Nilutamide—Leukopenia—Docetaxel—ovarian cancer	0.000443	0.00145	CcSEcCtD
Nilutamide—Loss of consciousness—Docetaxel—ovarian cancer	0.000435	0.00143	CcSEcCtD
Nilutamide—Weight decreased—Epirubicin—ovarian cancer	0.000433	0.00142	CcSEcCtD
Nilutamide—Hyperglycaemia—Epirubicin—ovarian cancer	0.000432	0.00142	CcSEcCtD
Nilutamide—Cough—Docetaxel—ovarian cancer	0.000432	0.00142	CcSEcCtD
Nilutamide—Angina pectoris—Doxorubicin—ovarian cancer	0.000432	0.00142	CcSEcCtD
Nilutamide—Insomnia—Paclitaxel—ovarian cancer	0.000431	0.00141	CcSEcCtD
Nilutamide—Pneumonia—Epirubicin—ovarian cancer	0.000429	0.00141	CcSEcCtD
Nilutamide—Paraesthesia—Paclitaxel—ovarian cancer	0.000428	0.0014	CcSEcCtD
Nilutamide—AR—FOXA1 transcription factor network—ESR1—ovarian cancer	0.000427	0.00909	CbGpPWpGaD
Nilutamide—Hypertension—Docetaxel—ovarian cancer	0.000427	0.0014	CcSEcCtD
Nilutamide—Dyspnoea—Paclitaxel—ovarian cancer	0.000425	0.00139	CcSEcCtD
Nilutamide—Chest pain—Docetaxel—ovarian cancer	0.000421	0.00138	CcSEcCtD
Nilutamide—Nausea—Vinorelbine—ovarian cancer	0.000421	0.00138	CcSEcCtD
Nilutamide—Dyspepsia—Paclitaxel—ovarian cancer	0.000419	0.00138	CcSEcCtD
Nilutamide—Urinary tract infection—Epirubicin—ovarian cancer	0.000415	0.00136	CcSEcCtD
Nilutamide—Decreased appetite—Paclitaxel—ovarian cancer	0.000414	0.00136	CcSEcCtD
Nilutamide—Dry mouth—Docetaxel—ovarian cancer	0.000412	0.00135	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000412	0.00135	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000411	0.00135	CcSEcCtD
Nilutamide—Sweating—Epirubicin—ovarian cancer	0.000409	0.00134	CcSEcCtD
Nilutamide—Constipation—Paclitaxel—ovarian cancer	0.000407	0.00134	CcSEcCtD
Nilutamide—Pain—Paclitaxel—ovarian cancer	0.000407	0.00134	CcSEcCtD
Nilutamide—Haematuria—Epirubicin—ovarian cancer	0.000407	0.00134	CcSEcCtD
Nilutamide—Oedema—Docetaxel—ovarian cancer	0.000404	0.00132	CcSEcCtD
Nilutamide—Weight decreased—Doxorubicin—ovarian cancer	0.000401	0.00132	CcSEcCtD
Nilutamide—Hyperglycaemia—Doxorubicin—ovarian cancer	0.0004	0.00131	CcSEcCtD
Nilutamide—Pneumonia—Doxorubicin—ovarian cancer	0.000397	0.0013	CcSEcCtD
Nilutamide—Shock—Docetaxel—ovarian cancer	0.000397	0.0013	CcSEcCtD
Nilutamide—CYP2C19—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.000397	0.00844	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND2—ovarian cancer	0.000397	0.00843	CbGpPWpGaD
Nilutamide—Feeling abnormal—Paclitaxel—ovarian cancer	0.000392	0.00129	CcSEcCtD
Nilutamide—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000389	0.00128	CcSEcCtD
Nilutamide—Anorexia—Docetaxel—ovarian cancer	0.000385	0.00126	CcSEcCtD
Nilutamide—Rhinitis—Epirubicin—ovarian cancer	0.000384	0.00126	CcSEcCtD
Nilutamide—Urinary tract infection—Doxorubicin—ovarian cancer	0.000384	0.00126	CcSEcCtD
Nilutamide—Hypoaesthesia—Epirubicin—ovarian cancer	0.000381	0.00125	CcSEcCtD
Nilutamide—AR—Nuclear Receptor transcription pathway—ESR1—ovarian cancer	0.00038	0.00808	CbGpPWpGaD
Nilutamide—Sweating—Doxorubicin—ovarian cancer	0.000379	0.00124	CcSEcCtD
Nilutamide—Urinary tract disorder—Epirubicin—ovarian cancer	0.000378	0.00124	CcSEcCtD
Nilutamide—Oedema peripheral—Epirubicin—ovarian cancer	0.000378	0.00124	CcSEcCtD
Nilutamide—Haematuria—Doxorubicin—ovarian cancer	0.000377	0.00124	CcSEcCtD
Nilutamide—Body temperature increased—Paclitaxel—ovarian cancer	0.000377	0.00124	CcSEcCtD
Nilutamide—Abdominal pain—Paclitaxel—ovarian cancer	0.000377	0.00124	CcSEcCtD
Nilutamide—Urethral disorder—Epirubicin—ovarian cancer	0.000376	0.00123	CcSEcCtD
Nilutamide—Visual impairment—Epirubicin—ovarian cancer	0.000369	0.00121	CcSEcCtD
Nilutamide—Insomnia—Docetaxel—ovarian cancer	0.000365	0.0012	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—BRCA1—ovarian cancer	0.000364	0.00774	CbGpPWpGaD
Nilutamide—Paraesthesia—Docetaxel—ovarian cancer	0.000362	0.00119	CcSEcCtD
Nilutamide—Dyspnoea—Docetaxel—ovarian cancer	0.00036	0.00118	CcSEcCtD
Nilutamide—Rhinitis—Doxorubicin—ovarian cancer	0.000356	0.00117	CcSEcCtD
Nilutamide—Dyspepsia—Docetaxel—ovarian cancer	0.000355	0.00117	CcSEcCtD
Nilutamide—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000353	0.00116	CcSEcCtD
Nilutamide—Decreased appetite—Docetaxel—ovarian cancer	0.000351	0.00115	CcSEcCtD
Nilutamide—Urinary tract disorder—Doxorubicin—ovarian cancer	0.00035	0.00115	CcSEcCtD
Nilutamide—Oedema peripheral—Doxorubicin—ovarian cancer	0.000349	0.00115	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—MSH2—ovarian cancer	0.000349	0.00743	CbGpPWpGaD
Nilutamide—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000349	0.00114	CcSEcCtD
Nilutamide—Urethral disorder—Doxorubicin—ovarian cancer	0.000348	0.00114	CcSEcCtD
Nilutamide—Constipation—Docetaxel—ovarian cancer	0.000345	0.00113	CcSEcCtD
Nilutamide—Pain—Docetaxel—ovarian cancer	0.000345	0.00113	CcSEcCtD
Nilutamide—Visual impairment—Doxorubicin—ovarian cancer	0.000342	0.00112	CcSEcCtD
Nilutamide—Asthenia—Paclitaxel—ovarian cancer	0.000342	0.00112	CcSEcCtD
Nilutamide—Alopecia—Epirubicin—ovarian cancer	0.000339	0.00111	CcSEcCtD
Nilutamide—Pruritus—Paclitaxel—ovarian cancer	0.000337	0.00111	CcSEcCtD
Nilutamide—Feeling abnormal—Docetaxel—ovarian cancer	0.000333	0.00109	CcSEcCtD
Nilutamide—Gastrointestinal pain—Docetaxel—ovarian cancer	0.00033	0.00108	CcSEcCtD
Nilutamide—Tension—Epirubicin—ovarian cancer	0.000327	0.00107	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—SMARCA4—ovarian cancer	0.000326	0.00694	CbGpPWpGaD
Nilutamide—Diarrhoea—Paclitaxel—ovarian cancer	0.000326	0.00107	CcSEcCtD
Nilutamide—Nervousness—Epirubicin—ovarian cancer	0.000324	0.00106	CcSEcCtD
Nilutamide—Back pain—Epirubicin—ovarian cancer	0.000323	0.00106	CcSEcCtD
Nilutamide—Abdominal pain—Docetaxel—ovarian cancer	0.000319	0.00105	CcSEcCtD
Nilutamide—Body temperature increased—Docetaxel—ovarian cancer	0.000319	0.00105	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—CCNE1—ovarian cancer	0.000319	0.00678	CbGpPWpGaD
Nilutamide—Dizziness—Paclitaxel—ovarian cancer	0.000315	0.00103	CcSEcCtD
Nilutamide—Alopecia—Doxorubicin—ovarian cancer	0.000313	0.00103	CcSEcCtD
Nilutamide—Ill-defined disorder—Epirubicin—ovarian cancer	0.00031	0.00102	CcSEcCtD
Nilutamide—Anaemia—Epirubicin—ovarian cancer	0.000308	0.00101	CcSEcCtD
Nilutamide—Tension—Doxorubicin—ovarian cancer	0.000303	0.000994	CcSEcCtD
Nilutamide—Vomiting—Paclitaxel—ovarian cancer	0.000303	0.000993	CcSEcCtD
Nilutamide—AR—Nongenotropic Androgen signaling—MAPK3—ovarian cancer	0.000302	0.00643	CbGpPWpGaD
Nilutamide—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000302	0.00642	CbGpPWpGaD
Nilutamide—Malaise—Epirubicin—ovarian cancer	0.000301	0.000987	CcSEcCtD
Nilutamide—Rash—Paclitaxel—ovarian cancer	0.0003	0.000985	CcSEcCtD
Nilutamide—Dermatitis—Paclitaxel—ovarian cancer	0.0003	0.000984	CcSEcCtD
Nilutamide—Nervousness—Doxorubicin—ovarian cancer	0.0003	0.000984	CcSEcCtD
Nilutamide—Syncope—Epirubicin—ovarian cancer	0.000299	0.000982	CcSEcCtD
Nilutamide—Leukopenia—Epirubicin—ovarian cancer	0.000299	0.00098	CcSEcCtD
Nilutamide—Back pain—Doxorubicin—ovarian cancer	0.000299	0.00098	CcSEcCtD
Nilutamide—Headache—Paclitaxel—ovarian cancer	0.000298	0.000979	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—ovarian cancer	0.000297	0.00632	CbGpPWpGaD
Nilutamide—Loss of consciousness—Epirubicin—ovarian cancer	0.000293	0.000962	CcSEcCtD
Nilutamide—Cough—Epirubicin—ovarian cancer	0.000291	0.000955	CcSEcCtD
Nilutamide—AR—FOXA1 transcription factor network—CDKN1B—ovarian cancer	0.000291	0.00618	CbGpPWpGaD
Nilutamide—Asthenia—Docetaxel—ovarian cancer	0.00029	0.00095	CcSEcCtD
Nilutamide—Hypertension—Epirubicin—ovarian cancer	0.000288	0.000945	CcSEcCtD
Nilutamide—AR—Nongenotropic Androgen signaling—MAPK1—ovarian cancer	0.000288	0.00612	CbGpPWpGaD
Nilutamide—CYP2C8—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000287	0.00611	CbGpPWpGaD
Nilutamide—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000286	0.00094	CcSEcCtD
Nilutamide—Pruritus—Docetaxel—ovarian cancer	0.000286	0.000937	CcSEcCtD
Nilutamide—Anaemia—Doxorubicin—ovarian cancer	0.000285	0.000936	CcSEcCtD
Nilutamide—Chest pain—Epirubicin—ovarian cancer	0.000284	0.000932	CcSEcCtD
Nilutamide—Nausea—Paclitaxel—ovarian cancer	0.000283	0.000928	CcSEcCtD
Nilutamide—Discomfort—Epirubicin—ovarian cancer	0.000281	0.000921	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—GADD45A—ovarian cancer	0.000279	0.00593	CbGpPWpGaD
Nilutamide—Malaise—Doxorubicin—ovarian cancer	0.000278	0.000913	CcSEcCtD
Nilutamide—Dry mouth—Epirubicin—ovarian cancer	0.000278	0.000911	CcSEcCtD
Nilutamide—Syncope—Doxorubicin—ovarian cancer	0.000277	0.000908	CcSEcCtD
Nilutamide—Leukopenia—Doxorubicin—ovarian cancer	0.000276	0.000907	CcSEcCtD
Nilutamide—Diarrhoea—Docetaxel—ovarian cancer	0.000276	0.000906	CcSEcCtD
Nilutamide—AR—Notch-mediated HES/HEY network—CDKN1B—ovarian cancer	0.000276	0.00586	CbGpPWpGaD
Nilutamide—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000275	0.00585	CbGpPWpGaD
Nilutamide—Oedema—Epirubicin—ovarian cancer	0.000272	0.000893	CcSEcCtD
Nilutamide—Loss of consciousness—Doxorubicin—ovarian cancer	0.000271	0.00089	CcSEcCtD
Nilutamide—Cough—Doxorubicin—ovarian cancer	0.000269	0.000884	CcSEcCtD
Nilutamide—Shock—Epirubicin—ovarian cancer	0.000268	0.000879	CcSEcCtD
Nilutamide—Dizziness—Docetaxel—ovarian cancer	0.000267	0.000876	CcSEcCtD
Nilutamide—Hypertension—Doxorubicin—ovarian cancer	0.000267	0.000874	CcSEcCtD
Nilutamide—Hyperhidrosis—Epirubicin—ovarian cancer	0.000263	0.000864	CcSEcCtD
Nilutamide—Chest pain—Doxorubicin—ovarian cancer	0.000263	0.000862	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—ESR1—ovarian cancer	0.000262	0.00558	CbGpPWpGaD
Nilutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000262	0.00558	CbGpPWpGaD
Nilutamide—Discomfort—Doxorubicin—ovarian cancer	0.00026	0.000852	CcSEcCtD
Nilutamide—Anorexia—Epirubicin—ovarian cancer	0.00026	0.000852	CcSEcCtD
Nilutamide—Dry mouth—Doxorubicin—ovarian cancer	0.000257	0.000843	CcSEcCtD
Nilutamide—Vomiting—Docetaxel—ovarian cancer	0.000257	0.000842	CcSEcCtD
Nilutamide—CYP2C19—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000257	0.00546	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CHEK2—ovarian cancer	0.000255	0.00541	CbGpPWpGaD
Nilutamide—Rash—Docetaxel—ovarian cancer	0.000255	0.000835	CcSEcCtD
Nilutamide—Dermatitis—Docetaxel—ovarian cancer	0.000254	0.000834	CcSEcCtD
Nilutamide—Headache—Docetaxel—ovarian cancer	0.000253	0.00083	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—CAV1—ovarian cancer	0.000252	0.00537	CbGpPWpGaD
Nilutamide—Oedema—Doxorubicin—ovarian cancer	0.000252	0.000827	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—APC—ovarian cancer	0.00025	0.00533	CbGpPWpGaD
Nilutamide—AR—Nongenotropic Androgen signaling—PIK3CA—ovarian cancer	0.00025	0.00531	CbGpPWpGaD
Nilutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000248	0.00528	CbGpPWpGaD
Nilutamide—Shock—Doxorubicin—ovarian cancer	0.000248	0.000813	CcSEcCtD
Nilutamide—AR—Generic Transcription Pathway—NR5A1—ovarian cancer	0.000247	0.00525	CbGpPWpGaD
Nilutamide—Insomnia—Epirubicin—ovarian cancer	0.000246	0.000808	CcSEcCtD
Nilutamide—CYP2C8—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000245	0.00521	CbGpPWpGaD
Nilutamide—Paraesthesia—Epirubicin—ovarian cancer	0.000245	0.000802	CcSEcCtD
Nilutamide—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000244	0.000799	CcSEcCtD
Nilutamide—Dyspnoea—Epirubicin—ovarian cancer	0.000243	0.000796	CcSEcCtD
Nilutamide—Anorexia—Doxorubicin—ovarian cancer	0.00024	0.000788	CcSEcCtD
Nilutamide—Nausea—Docetaxel—ovarian cancer	0.00024	0.000787	CcSEcCtD
Nilutamide—Dyspepsia—Epirubicin—ovarian cancer	0.00024	0.000786	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—BRCA1—ovarian cancer	0.000239	0.00507	CbGpPWpGaD
Nilutamide—Decreased appetite—Epirubicin—ovarian cancer	0.000237	0.000777	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000235	0.000771	CcSEcCtD
Nilutamide—CYP2C9—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000234	0.00497	CbGpPWpGaD
Nilutamide—Pain—Epirubicin—ovarian cancer	0.000233	0.000764	CcSEcCtD
Nilutamide—Constipation—Epirubicin—ovarian cancer	0.000233	0.000764	CcSEcCtD
Nilutamide—AR—Nongenotropic Androgen signaling—HRAS—ovarian cancer	0.000231	0.00491	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.000231	0.00491	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—ovarian cancer	0.00023	0.0049	CbGpPWpGaD
Nilutamide—Insomnia—Doxorubicin—ovarian cancer	0.000228	0.000748	CcSEcCtD
Nilutamide—AR—Notch-mediated HES/HEY network—STAT3—ovarian cancer	0.000227	0.00483	CbGpPWpGaD
Nilutamide—Paraesthesia—Doxorubicin—ovarian cancer	0.000226	0.000742	CcSEcCtD
Nilutamide—Dyspnoea—Doxorubicin—ovarian cancer	0.000225	0.000737	CcSEcCtD
Nilutamide—Feeling abnormal—Epirubicin—ovarian cancer	0.000224	0.000736	CcSEcCtD
Nilutamide—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000223	0.00073	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—ovarian cancer	0.000222	0.00472	CbGpPWpGaD
Nilutamide—Dyspepsia—Doxorubicin—ovarian cancer	0.000222	0.000728	CcSEcCtD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000222	0.00472	CbGpPWpGaD
Nilutamide—Decreased appetite—Doxorubicin—ovarian cancer	0.000219	0.000719	CcSEcCtD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000219	0.00465	CbGpPWpGaD
Nilutamide—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000218	0.000714	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—BRCA2—ovarian cancer	0.000216	0.00459	CbGpPWpGaD
Nilutamide—Pain—Doxorubicin—ovarian cancer	0.000215	0.000707	CcSEcCtD
Nilutamide—Constipation—Doxorubicin—ovarian cancer	0.000215	0.000707	CcSEcCtD
Nilutamide—Abdominal pain—Epirubicin—ovarian cancer	0.000215	0.000706	CcSEcCtD
Nilutamide—Body temperature increased—Epirubicin—ovarian cancer	0.000215	0.000706	CcSEcCtD
Nilutamide—AR—Coregulation of Androgen receptor activity—CCND1—ovarian cancer	0.000213	0.00454	CbGpPWpGaD
Nilutamide—AR—Coregulation of Androgen receptor activity—CTNNB1—ovarian cancer	0.000211	0.00449	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000211	0.00449	CbGpPWpGaD
Nilutamide—Feeling abnormal—Doxorubicin—ovarian cancer	0.000208	0.000681	CcSEcCtD
Nilutamide—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000206	0.000676	CcSEcCtD
Nilutamide—AR—Nongenotropic Androgen signaling—AKT1—ovarian cancer	0.000204	0.00434	CbGpPWpGaD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000202	0.0043	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000201	0.00428	CbGpPWpGaD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.0002	0.00424	CbGpPWpGaD
Nilutamide—Body temperature increased—Doxorubicin—ovarian cancer	0.000199	0.000653	CcSEcCtD
Nilutamide—Abdominal pain—Doxorubicin—ovarian cancer	0.000199	0.000653	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000198	0.0042	CbGpPWpGaD
Nilutamide—Asthenia—Epirubicin—ovarian cancer	0.000195	0.000641	CcSEcCtD
Nilutamide—Pruritus—Epirubicin—ovarian cancer	0.000193	0.000632	CcSEcCtD
Nilutamide—Diarrhoea—Epirubicin—ovarian cancer	0.000186	0.000611	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—ovarian cancer	0.000184	0.00392	CbGpPWpGaD
Nilutamide—Asthenia—Doxorubicin—ovarian cancer	0.000181	0.000593	CcSEcCtD
Nilutamide—Dizziness—Epirubicin—ovarian cancer	0.00018	0.000591	CcSEcCtD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.00018	0.00382	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.000179	0.0038	CbGpPWpGaD
Nilutamide—Pruritus—Doxorubicin—ovarian cancer	0.000178	0.000585	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.000173	0.00368	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.000173	0.00368	CbGpPWpGaD
Nilutamide—Vomiting—Epirubicin—ovarian cancer	0.000173	0.000568	CcSEcCtD
Nilutamide—Diarrhoea—Doxorubicin—ovarian cancer	0.000172	0.000566	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—ovarian cancer	0.000172	0.00365	CbGpPWpGaD
Nilutamide—Rash—Epirubicin—ovarian cancer	0.000172	0.000563	CcSEcCtD
Nilutamide—Dermatitis—Epirubicin—ovarian cancer	0.000172	0.000563	CcSEcCtD
Nilutamide—Headache—Epirubicin—ovarian cancer	0.000171	0.00056	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—ovarian cancer	0.00017	0.00362	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.00017	0.00362	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—ovarian cancer	0.000167	0.00355	CbGpPWpGaD
Nilutamide—AR—Gene Expression—WDR77—ovarian cancer	0.000167	0.00354	CbGpPWpGaD
Nilutamide—Dizziness—Doxorubicin—ovarian cancer	0.000167	0.000547	CcSEcCtD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000164	0.00349	CbGpPWpGaD
Nilutamide—Nausea—Epirubicin—ovarian cancer	0.000162	0.000531	CcSEcCtD
Nilutamide—Vomiting—Doxorubicin—ovarian cancer	0.00016	0.000526	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—ESR1—ovarian cancer	0.000159	0.00339	CbGpPWpGaD
Nilutamide—Rash—Doxorubicin—ovarian cancer	0.000159	0.000521	CcSEcCtD
Nilutamide—Dermatitis—Doxorubicin—ovarian cancer	0.000159	0.000521	CcSEcCtD
Nilutamide—Headache—Doxorubicin—ovarian cancer	0.000158	0.000518	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—CCND1—ovarian cancer	0.000158	0.00335	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—CTNNB1—ovarian cancer	0.000156	0.00332	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—PTEN—ovarian cancer	0.000152	0.00324	CbGpPWpGaD
Nilutamide—Nausea—Doxorubicin—ovarian cancer	0.00015	0.000491	CcSEcCtD
Nilutamide—AR—Generic Transcription Pathway—YAP1—ovarian cancer	0.000141	0.00299	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CDH1—ovarian cancer	0.000139	0.00295	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—ovarian cancer	0.000138	0.00293	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—ovarian cancer	0.000136	0.0029	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—STAT3—ovarian cancer	0.000136	0.0029	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.000132	0.00281	CbGpPWpGaD
Nilutamide—AR—Gene Expression—TTF1—ovarian cancer	0.000131	0.00278	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000125	0.00265	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—EGFR—ovarian cancer	0.000124	0.00263	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—PGR—ovarian cancer	0.000123	0.00261	CbGpPWpGaD
Nilutamide—AR—Gene Expression—NR5A1—ovarian cancer	0.000119	0.00253	CbGpPWpGaD
Nilutamide—AR—Coregulation of Androgen receptor activity—AKT1—ovarian cancer	0.000119	0.00252	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—MTOR—ovarian cancer	0.000115	0.00245	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—PARP1—ovarian cancer	0.000114	0.00243	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	0.000108	0.0023	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP1B1—ovarian cancer	0.000107	0.00227	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CASP3—ovarian cancer	0.000106	0.00226	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000106	0.00224	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CASP3—ovarian cancer	0.000103	0.0022	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CCND1—ovarian cancer	0.000103	0.0022	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CTNNB1—ovarian cancer	0.000102	0.00218	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—PTEN—ovarian cancer	9.98e-05	0.00212	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	9.97e-05	0.00212	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	9.69e-05	0.00206	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP1B1—ovarian cancer	9.55e-05	0.00203	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—ovarian cancer	9.46e-05	0.00201	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP1B1—ovarian cancer	9.42e-05	0.002	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—VEGFA—ovarian cancer	9.01e-05	0.00192	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	8.98e-05	0.00191	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	8.8e-05	0.00187	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	8.78e-05	0.00187	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—AKT1—ovarian cancer	8.78e-05	0.00187	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP1B1—ovarian cancer	8.71e-05	0.00185	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP1B1—ovarian cancer	8.59e-05	0.00183	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	8.56e-05	0.00182	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	8.48e-05	0.0018	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—MYC—ovarian cancer	8.29e-05	0.00176	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	8.27e-05	0.00176	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	8.25e-05	0.00175	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—MAPK1—ovarian cancer	8.11e-05	0.00172	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—EGFR—ovarian cancer	8.11e-05	0.00172	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—KRAS—ovarian cancer	7.66e-05	0.00163	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	7.47e-05	0.00159	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	7.36e-05	0.00157	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	7.06e-05	0.0015	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	6.87e-05	0.00146	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—TP53—ovarian cancer	6.81e-05	0.00145	CbGpPWpGaD
Nilutamide—AR—Gene Expression—YAP1—ovarian cancer	6.77e-05	0.00144	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	6.72e-05	0.00143	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	6.72e-05	0.00143	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	6.71e-05	0.00143	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—ESR1—ovarian cancer	6.56e-05	0.00139	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NME2—ovarian cancer	6.52e-05	0.00139	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	6.35e-05	0.00135	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—IL6—ovarian cancer	6.07e-05	0.00129	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PGR—ovarian cancer	5.92e-05	0.00126	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	5.83e-05	0.00124	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—NME2—ovarian cancer	5.82e-05	0.00124	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	5.75e-05	0.00122	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	5.64e-05	0.0012	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	5.53e-05	0.00118	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PARP1—ovarian cancer	5.5e-05	0.00117	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NME2—ovarian cancer	5.31e-05	0.00113	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	4.94e-05	0.00105	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	4.76e-05	0.00101	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	4.51e-05	0.000959	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	4.5e-05	0.000958	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PPP2R1A—ovarian cancer	4.46e-05	0.000949	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYTB—ovarian cancer	4.2e-05	0.000894	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.11e-05	0.000874	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	4.03e-05	0.000856	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYTB—ovarian cancer	3.75e-05	0.000798	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—BRIP1—ovarian cancer	3.67e-05	0.000781	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PPP1CC—ovarian cancer	3.67e-05	0.000781	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	3.67e-05	0.000781	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	3.67e-05	0.00078	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYTB—ovarian cancer	3.42e-05	0.000727	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—MYC—ovarian cancer	3.41e-05	0.000726	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	3.34e-05	0.000711	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—BRIP1—ovarian cancer	3.28e-05	0.000697	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PPP1CC—ovarian cancer	3.28e-05	0.000697	CbGpPWpGaD
Nilutamide—AR—Gene Expression—ESR1—ovarian cancer	3.16e-05	0.000672	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PPP1CC—ovarian cancer	2.99e-05	0.000636	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—BRIP1—ovarian cancer	2.99e-05	0.000636	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.68e-05	0.000569	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—YAP1—ovarian cancer	2.46e-05	0.000524	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.44e-05	0.000519	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.39e-05	0.000508	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—YAP1—ovarian cancer	2.2e-05	0.000468	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.18e-05	0.000463	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.18e-05	0.000463	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.14e-05	0.000456	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—FASN—ovarian cancer	2.01e-05	0.000427	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—YAP1—ovarian cancer	2.01e-05	0.000426	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.98e-05	0.000422	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—SLC5A5—ovarian cancer	1.98e-05	0.00042	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.91e-05	0.000407	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—SLC2A1—ovarian cancer	1.91e-05	0.000406	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.87e-05	0.000397	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP1B1—ovarian cancer	1.83e-05	0.000389	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—FASN—ovarian cancer	1.79e-05	0.000381	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—SLC5A5—ovarian cancer	1.76e-05	0.000375	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.74e-05	0.000371	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—SLC2A1—ovarian cancer	1.7e-05	0.000362	CbGpPWpGaD
Nilutamide—AR—Gene Expression—MAPK3—ovarian cancer	1.69e-05	0.000359	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.67e-05	0.000355	CbGpPWpGaD
Nilutamide—AR—Gene Expression—MYC—ovarian cancer	1.64e-05	0.000349	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—FASN—ovarian cancer	1.64e-05	0.000348	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP1B1—ovarian cancer	1.63e-05	0.000347	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	1.62e-05	0.000345	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.61e-05	0.000343	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—SLC5A5—ovarian cancer	1.61e-05	0.000342	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—SLC2A1—ovarian cancer	1.55e-05	0.00033	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.52e-05	0.000323	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ABCB1—ovarian cancer	1.51e-05	0.00032	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP1B1—ovarian cancer	1.49e-05	0.000317	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—TYMS—ovarian cancer	1.48e-05	0.000315	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	1.45e-05	0.000308	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.44e-05	0.000306	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ABCB1—ovarian cancer	1.34e-05	0.000286	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—TYMS—ovarian cancer	1.32e-05	0.000281	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	1.32e-05	0.000281	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.31e-05	0.000279	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ABCB1—ovarian cancer	1.23e-05	0.000261	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—TYMS—ovarian cancer	1.2e-05	0.000256	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CAV1—ovarian cancer	1.19e-05	0.000254	CbGpPWpGaD
Nilutamide—AR—Gene Expression—AKT1—ovarian cancer	1.14e-05	0.000242	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.14e-05	0.000242	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PIK3CG—ovarian cancer	1.09e-05	0.000231	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CAV1—ovarian cancer	1.06e-05	0.000226	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.02e-05	0.000216	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CAV1—ovarian cancer	9.7e-06	0.000206	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PIK3CG—ovarian cancer	9.69e-06	0.000206	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PIK3CD—ovarian cancer	9.55e-06	0.000203	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	9.27e-06	0.000197	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PIK3CG—ovarian cancer	8.84e-06	0.000188	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PIK3CD—ovarian cancer	8.52e-06	0.000181	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PIK3CB—ovarian cancer	8.32e-06	0.000177	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PIK3CD—ovarian cancer	7.77e-06	0.000165	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PIK3CB—ovarian cancer	7.43e-06	0.000158	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PTEN—ovarian cancer	7.19e-06	0.000153	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PIK3CB—ovarian cancer	6.77e-06	0.000144	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PTEN—ovarian cancer	6.42e-06	0.000136	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PTEN—ovarian cancer	5.85e-06	0.000124	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PIK3CA—ovarian cancer	5.07e-06	0.000108	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PIK3CA—ovarian cancer	4.53e-06	9.63e-05	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—AKT1—ovarian cancer	4.14e-06	8.81e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PIK3CA—ovarian cancer	4.13e-06	8.78e-05	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—AKT1—ovarian cancer	3.7e-06	7.87e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—AKT1—ovarian cancer	3.37e-06	7.17e-05	CbGpPWpGaD
